Advocacy

NACDS expands recommendations for opioid abuse prevention
NACDS’ new policy recommendations for opioid abuse prevention build on existing initiatives to prevent abuse and to protect pain treatment.
Sen. Wyden visits NCPA board member’s community pharmacy
Sen. Ron Wyden, D-Ore., and Michele Belcher, a National Community Pharmacists Association board member and owner of Grants Pass Pharmacy, discussed efforts to reduce drug prices that are underway in the Senate Finance Committee.

NACDS RxImpact to Congress: Close pharmacy DIR fee loophole

NACDS has issued an action alert, urging Congress to provide DIR fee relief through the Phair Pricing Act.
NACDS, NCPA react to CMS' new drug pricing rule

NACDS, and NCPA reacted with disapproval after a final drug pricing rule excluded reforms to pharmacy DIR fees.
CMS issues new guidance addressing "spread pricing" in Medicaid

CMS' new guidance clarifies how current regulations require “spread pricing” to be accounted for in the calculation of Medical Loss Ratios.
AAM, Biosimilars Council oppose FDA biosimilar naming update

The Association for Accessible Medicines said the Food and Drug Administration's guidance on naming biological products delays the development of biosimilars.
NACDS’ Anderson continues to urge DIR fee relief in op-ed

NACDS' Steve Anderson continues to urge for DIR fee reform in anticipation of a Medicare rule that would provide relief from DIR fees.
NCPA's annual Congressional Fly-In tallied more than 600 Congressional visits

The National Community Pharmacists Association-hosted Congressional Fly-In event drew hundreds of community pharmacists from 39 states.
NACDS' Anderson urges drug abuse prevention bill sensitive to chronic pain patients’ needs

The Hill published a column by NACDS president and CEO Steve Anderson on a bill that would serve as a “safety” mechanism for the use of opioids in treating temporary, or acute, pain.
AmerisourceBergen supports transitioning pharmaceutical rebates to POS discounts

AmerisourceBergen supports policies that lower out-of-pocket costs for patients and will support a transition to a patient-centered model with distributors serving as chargeback administrators for a Jan. 1, 2020, start.

NACDS expands recommendations for opioid abuse prevention

Sen. Wyden visits NCPA board member’s community pharmacy

NACDS RxImpact to Congress: Close pharmacy DIR fee loophole

NACDS, NCPA react to CMS' new drug pricing rule

CMS issues new guidance addressing "spread pricing" in Medicaid

AAM, Biosimilars Council oppose FDA biosimilar naming update

NACDS’ Anderson continues to urge DIR fee relief in op-ed

NCPA's annual Congressional Fly-In tallied more than 600 Congressional visits

NACDS' Anderson urges drug abuse prevention bill sensitive to chronic pain patients’ needs

AmerisourceBergen supports transitioning pharmaceutical rebates to POS discounts